Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global in vitro diagnostics company that regularly issues news on its products, technologies and financial performance. As a manufacturer of diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho generates updates that are relevant to clinicians, laboratory professionals and investors who follow developments in medical diagnostics.
News about QuidelOrtho often covers product clearances and launches, such as FDA 510(k) clearance for the VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction, or the availability of the QUICKVUE Influenza + SARS Test, a CLIA‑waived rapid immunoassay that differentiates influenza A, influenza B and SARS‑CoV‑2 from a single sample. These announcements provide insight into how the company is expanding its cardiac, respiratory and point‑of‑care testing portfolios.
The company also issues financial and corporate updates, including quarterly earnings releases, guidance discussions and details of financing arrangements disclosed through press releases and related SEC filings. Investors can track how QuidelOrtho describes its revenue mix, cost‑savings initiatives and capital structure, including credit agreements and refinancing activities.
Another recurring theme in QuidelOrtho’s news flow is educational and thought‑leadership content. Through its Science Bytes podcast, the company highlights topics such as diagnostic trends, early detection of diabetes, the role of informatics in clinical decision‑making and the importance of respiratory testing in urgent care. Episodes feature internal experts and external clinicians and are used to explain how diagnostics intersect with patient care and healthcare economics.
In addition, QuidelOrtho reports on its participation in industry conferences, including events focused on transfusion medicine where it showcases immunohematology products like the MTS DAT Card and ORTHO VISION Platform. For users of this news page, following QDEL news offers a way to monitor product pipeline milestones, regulatory developments, financial disclosures and educational initiatives from a single diagnostics-focused source.
QuidelOrtho (Nasdaq: QDEL) released episode 56 of its Science Bytes podcast on Feb 19, 2026, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care.
The episode explains how high‑sensitivity troponin (hs troponin) enables earlier detection of cardiac injury, tighter reproducibility at low levels, shorter serial testing protocols (0/1 or 0/2 hour), sex‑specific cutoffs, and emerging applications in cardio‑oncology, perioperative care, and long‑term risk prediction.
QuidelOrtho (Nasdaq: QDEL) said members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference on Tuesday, March 3, 2026 at 1:40 p.m. ET / 10:40 a.m. PT.
According to the company, a live webcast and replay will be available in the Events & Presentations section of its Investor Relations website.
QuidelOrtho (Nasdaq: QDEL) reported fourth-quarter and full-year 2025 results: FY25 revenue $2.73B, adjusted EBITDA $597M with a 22% margin (up 240 bps), and adjusted diluted EPS $2.12. GAAP results included a $701M goodwill impairment, producing a FY25 GAAP net loss of $1.13B and GAAP diluted loss per share of $16.69. The company provided FY26 guidance of $2.7–$2.9B revenue, adjusted EBITDA $630–$670M, adjusted diluted EPS $2.00–$2.42, and free cash flow of $120–$160M. CFO Joseph Busky will retire effective June 30, 2026.
QuidelOrtho (Nasdaq: QDEL) received the Excellence Services Label in EMEA for Customer and Technical Services evaluated to ISO 23592 and is the first medical device company to earn that distinction. QuidelOrtho also won a Gold Stevie for Customer Service Success and a Bronze Stevie for AI & Tech Focused Digital Transformation Team.
The ISO 23592 scope covers Customer Service, Technical Solutions, Technical Training and Field Service; the label affirms maturity and consistent customer focus, while Stevie recognition highlights customer‑experience and digital transformation efforts.
QuidelOrtho (Nasdaq: QDEL) released episode 55 of its Science Bytes podcast on Jan 22, 2026, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. Mullens discusses pressures on the blood supply from routine trauma and climate-driven emergencies, rising demand for O-type units due to low-titer whole blood programs, the role of automation in immunohematology, and the importance of year-round donor engagement. The episode highlights the link between donors, diagnostics, and patient care and is available on major streaming platforms and the company's website.
QuidelOrtho (Nasdaq: QDEL) will report fourth quarter and full-year 2025 financial results for the period ended December 28, 2025, after market close on Wednesday, February 11, 2026. A conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET the same day, with presentation materials and a replay available in the Events & Presentations section of the company's Investor Relations website.
Investors can join the live webcast via the IR site or by phone at 833-470-1428 (U.S.) or +1 929-526-1599 (international) using Conference ID 690468.
QuidelOrtho (Nasdaq: QDEL) released Episode 54 of its Science Bytes podcast on Dec. 18, 2025, featuring Jonathan Siegrist, PhD, EVP of Research & Development and CTO.
Key topics include high-sensitivity troponin for faster cardiac diagnosis, non-invasive gastrointestinal assays, rapid combo respiratory tests, advances in molecular platforms, informatics and AI, and R&D strategies to scale diagnostic innovation globally. The episode discusses how these technologies streamline clinical workflows and support timely patient care decisions.
The podcast is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) announced that management will participate in two investor conferences in early December 2025: the Evercore ISI 8th Annual Healthcare Conference on December 2, 2025 with a fireside chat at 10:00 a.m. ET / 7:00 a.m. PT, and the Citi Global Healthcare Conference on December 3, 2025 with a fireside chat at 1:00 p.m. ET / 10:00 a.m. PT.
Investors can access the live webcasts and replays in the Events & Presentations section of QuidelOrtho's Investor Relations site at https://ir.quidelortho.com/.
QuidelOrtho (Nasdaq: QDEL) released Episode 53 of its Science Bytes podcast on Nov 20, 2025, featuring Dr. Qian Ding discussing early detection of diabetes.
Key points: early testing can change patient trajectories; emerging biomarkers (C-peptide, pro‑insulin, adiponectin) add metabolic insight beyond glucose; automation-ready lab platforms speed reliable results; early detection supports value-based care and may reduce costly interventions; tailored testing promotes equity across populations. The episode is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) launched the QUICKVUE Influenza + SARS Test, a CLIA‑waived, 510(k)‑cleared rapid immunoassay for professional use that detects and differentiates influenza A, influenza B and SARS‑CoV‑2 antigens from a single nasal swab.
The visually read combo test delivers results in as fast as 10 minutes, is designed for physician office labs, urgent care, emergency departments, pharmacies and decentralized hospital labs, and complements QuidelOrtho's instrumented SOFIA 2 Flu + SARS product as a cost‑effective point‑of‑care option. The test is available in the United States through existing distribution channels and is not intended for in‑home use.